CS
CTMX icon

Candriam SCA’s CytomX Therapeutics CTMX Stock Holding History

Candriam SCA’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-210,027
Closed -$256K – 692
2024
Q2 		$256K Buy
+210,027
New +$418K ﹤0.01% 672
2022
Q3 		– Sell
-1,653,988
Closed -$3.03M – 876
2022
Q2 		$3.03M Hold
1,653,988
– – 0.02% 412
2022
Q1 		$4.42M Sell
1,653,988
-106,934
-6% -$411K 0.03% 375
2021
Q4 		$7.62M Sell
1,760,922
-1,545,018
-47% -$9.05M 0.05% 298
2021
Q3 		$16.8M Buy
3,305,940
+977,587
+42% +$5.23M 0.11% 199
2021
Q2 		$14.7M Buy
2,328,353
+2,328,207
+1,594,662% +$18.1M 0.1% 232
2021
Q1 		$1K Buy
+146
New +$1.16K ﹤0.01% 793
2020
Q2 		– Sell
-741,191
Closed -$6.02M – 818
2020
Q1 		$6.02M Buy
741,191
+47
+0% +$328 0.07% 303
2019
Q4 		$6.16M Buy
741,144
+53,311
+8% +$360K 0.07% 309
2019
Q3 		$5.08M Hold
687,833
– – 0.07% 314
2019
Q2 		$7.68M Buy
687,833
+19,000
+3% +$199K 0.1% 235
2019
Q1 		$7.19M Buy
668,833
+177,845
+36% +$2.63M 0.09% 250
2018
Q4 		$7.41M Buy
490,988
+98,261
+25% +$1.46M 0.11% 210
2018
Q3 		$7.26M Buy
392,727
+212,600
+118% +$4.84M 0.1% 247
2018
Q2 		$4.12M Buy
180,127
+139,127
+339% +$3.55M 0.07% 335
2018
Q1 		$1.17M Sell
41,000
-48,000
-54% -$1.37M 0.02% 568
2017
Q4 		$1.88M Sell
89,000
-76,000
-46% -$1.58M 0.03% 467
2017
Q3 		$3M Sell
165,000
-30,000
-15% -$468K 0.05% 370
2017
Q2 		$3.02M Hold
195,000
– – 0.06% 380
2017
Q1 		$3.37M Buy
195,000
+40,000
+26% +$526K 0.07% 343
2016
Q4 		$1.7M Hold
155,000
– – 0.04% 399
2016
Q3 		$2.43M Buy
155,000
+88,000
+131% +$1.06M 0.06% 318
2016
Q2 		$684K Buy
67,000
+25,000
+60% +$285K 0.02% 508
2016
Q1 		$539K Buy
42,000
+32,000
+320% +$444K 0.01% 536
2015
Q4 		$209K Buy
+10,000
New +$158K 0.01% 537

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Candriam SCA's CTMX Position: Q3 2024 in Review

Candriam SCA sold out of CytomX Therapeutics (CTMX) in Q3 2024, closing a stake of 210,027 shares — an estimated $256K sold.

Candriam SCA first reported a position in CTMX in Q4 2015 and held it in 25 quarters. The position peaked at $16.8M in Q3 2021. 69 funds tracked by Wall St. Rank hold CTMX as of Q3 2024.

  • Candriam SCA reported no remaining CytomX Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Candriam SCA sold 210,027 CytomX Therapeutics shares in Q3 2024, an estimated $256K.
  • Candriam SCA first reported a position in CytomX Therapeutics in Q4 2015 and held it in 25 quarters.
  • Candriam SCA's CytomX Therapeutics position peaked at $16.8M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2024.

Based on Candriam SCA's 13F filing for Q3 2024, filed 13 Nov 2024.